Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Resverlogix Corp (RVX.TO)

Resverlogix Corp (RVX.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Resverlogix Corp 4820 Richard Road South West Suite 300 Calgary AB T3E 6L1 CAN

https://www.resverlogix.com P: 403-254-9252 F: 403-256-8495

Description:

Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.

Key Statistics

Overview:

Market Capitalization, $K 16,618
Shares Outstanding, K 276,969
Annual Sales, $ 0 K
Annual Net Income, $ -16,741 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -4,507 K
60-Month Beta 1.25
% of Institutional Shareholders 0.01%

Growth:

1-Year Return -14.29%
3-Year Return -86.36%
5-Year Return -95.71%
5-Year Revenue Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.02 on 08/14/24
Next Earnings Date 11/14/24
Earnings Per Share ttm -0.04
EPS Growth vs. Prev Qtr 100.00%
EPS Growth vs. Prev Year 56.58%
Dividend Payout Ratio 0.00%

RVX.TO Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % N/A
Return-on-Assets % -138.80%
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Book N/A
Book Value/Share -0.39
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar